The ASSURE study: HIV‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir

OBJECTIVES: HIV treatment guidelines endorse switching or simplification of antiretroviral therapy in therapy‐experienced patients with suppressed viraemia; ritonavir discontinuation may also enhance tolerability and reduce long‐term adverse events (AEs). This open‐label, multicentre, noninferiority...

Descripción completa

Detalles Bibliográficos
Autores principales: Wohl, DA, Bhatti, L, Small, CB, Edelstein, H, Zhao, HH, Margolis, DA, DeJesus, E, Weinberg, WG, Ross, LL, Shaefer, MS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034844/
https://www.ncbi.nlm.nih.gov/pubmed/26176344
http://dx.doi.org/10.1111/hiv.12281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034844/
https://www.ncbi.nlm.nih.gov/pubmed/26176344
http://dx.doi.org/10.1111/hiv.12281

Ejemplares similares